There are currently no clearly defined parameters available for therapy management, as the updated S3 guideline on the diagnosis and treatment of Crohn’s disease published last year states. This is a dilemma that raises the question of other indicators for evaluating the course of treatment. In the PROFILE study, a treatment strategy involving the early use of a biologic proved to be superior to the standard procedure in terms of steroid-free and surgery-free remission.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Crohn's disease and depression
Significant psychological stress for CD patients
- Epilepsy
Cannabidiol for refractory epilepsy syndromes
- Stomach cancer and Helicobacter pylori
A question of income?
- Prurigo nodularis and AD
Effective itch relief through inhibition of the IL-31 signaling pathway
- Cutaneous Crohn's disease
Effective alternative to TNF inhibitors
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Benralizumab in a patient with asthma and EGPA
When the biologic has a counterproductive effect
- Brain atrophy and MS